Latest news
25 items- SECSEC Form 15-12G filed by IMV Inc.15-12G - IMV Inc. (0001734768) (Filer)
- SECSEC Form F-10POS filed by IMV Inc.F-10POS - IMV Inc. (0001734768) (Filer)
- SECSEC Form F-10POS filed by IMV Inc.F-10POS - IMV Inc. (0001734768) (Filer)
- SECSEC Form F-10POS filed by IMV Inc.F-10POS - IMV Inc. (0001734768) (Filer)
- SECSEC Form S-8 POS filed by IMV Inc.S-8 POS - IMV Inc. (0001734768) (Filer)
- SECSEC Form S-8 POS filed by IMV Inc.S-8 POS - IMV Inc. (0001734768) (Filer)
- SECSEC Form S-8 POS filed by IMV Inc.S-8 POS - IMV Inc. (0001734768) (Filer)
- SECSEC Form S-8 POS filed by IMV Inc.S-8 POS - IMV Inc. (0001734768) (Filer)
- SECSEC Form S-8 POS filed by IMV Inc.S-8 POS - IMV Inc. (0001734768) (Filer)
- SECSEC Form 6-K filed by IMV Inc.6-K - IMV Inc. (0001734768) (Filer)
- SECSEC Form 25-NSE filed by IMV Inc.25-NSE - IMV Inc. (0001734768) (Subject)
- SECSEC Form 6-K filed by IMV Inc.6-K - IMV Inc. (0001734768) (Filer)
- PRIMV Receives NASDAQ Delisting NoticeIMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the "Initial Order") granting the Company and its subsidiaries prote
- PRHorizon Technology Finance Announces First Quarter 2023 Financial Results- First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and
- NEWSBenzinga's Top Ratings Upgrades, Downgrades For May 2, 2023Upgrades According to Colliers Securities, the prior rating for Centerspace (NYSE:CSR) was changed from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $1.07, compared to $0.98 from the year-ago quarter. The stock has a 52-week-high of $96.84 and a 52-week-low of $51.26. At the end of the last trading period, Centerspace closed at $56.87. According to Bernstein, the prior rating for Roper Technologies Inc (NYSE:ROP) was changed from Market Perform to Outperform. Roper Techs earned $3.90 in the first quarter, compared to $3.77 in the year-ago quarter. At the moment, the stock has a 52-week-high of $481.65 and a 52-week-low of $357.25. Roper Techs closed at $458.63 at the
- NEWSHC Wainwright & Co. Downgrades IMV to NeutralHC Wainwright & Co. analyst Joseph Pantginis downgrades IMV (NASDAQ:IMV) from Buy to Neutral.
- NEWSIMV Initiates Restructuring Proceedings Under The CCAA To Complete The Review Of Its Strategic AlternativesIMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA"). The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.After a careful review of available opt
- PRIMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic AlternativesIMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA"). The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. After a careful review of available
- NEWSIMV Shares Were Halted At 4:00 AM ET, News Pending
- NEWSWhy Bed Bath & Beyond Shares Are Trading Lower By 23%; Here Are 20 Stocks Moving PremarketGainers Clearmind Medicine Inc. (NASDAQ:CMND) gained 61.5% to $0.88 in pre-market trading after dropping around 3% on Tuesday. Clearmind engaged a contract research organization for its upcoming first-in-human study of MEAI compound while also filing an additional provisional patent application with partner SciSparc. SAI.TECH Global Corporation (NASDAQ:SAI) shares climbed 25.1% to $3.49 in pre-market trading after gaining 9% on Tuesday. SAI.TECH Global recently anounced appointments of Harry Sun to be Chief Technology Officer and Tao Wu to be Chief Operating Officer of SAI.TECH's new Product Line ULTIAAS. IN8bio, Inc. (NASDAQ:INAB) gained 20.4% to $2.30 in pre-market trading after drop
- SECSEC Form 6-K filed by IMV Inc.6-K - IMV Inc. (0001734768) (Filer)
- NEWSIMV Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyIMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that, based upon the closing bid price of the Company's common shares for the 30 consecutive business day period between February 14, 2023, through March 28, 2023, the Company did not meet the minimum bid price of US$1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listin
- PRIMV Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyIMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that, based upon the closing bid price of the Company's common shares for the 30 consecutive business day period between February 14, 2023, through March 28, 2023, the Company did not meet the minimum bid price of US$1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listi
- SECSEC Form 6-K filed by IMV Inc.6-K - IMV Inc. (0001734768) (Filer)
- PRIMV Inc. Announces Changes to Its Board of DirectorsIMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors ("Board") of the Company, effective immediately. Dr. Tilley, Managing Partner at CTI Life Sciences Fund ("CTI LSF"), was originally appointed to the IMV Board in 2016 as a representative from CTI LSF following their initial investment in IMV. Dr. Tilley's resignation arose due to policy changes surrounding board positions at CTI LSF and she will remain IMV's point of contact at CTI LSF.
IMV FAQ
6 questionsWhat does IMV Inc. do?
IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute...Where does IMV stock trade?
IMV Inc. (IMV) is listed on NASDAQ.What sector and industry is IMV in?
IMV Inc. operates in the Health Care sector, Pharmaceuticals and Biotechnology industry.What are analysts saying about IMV?
IMV Inc. has had 2 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $400.00 price target on 2021-09-22. Recent price targets range from $400.00 to $1400.00.What companies are similar to IMV?
Notable peers in the same industry include EPRX (Eupraxia Pharmaceuticals Inc.), ZOM (Zomedica Corp.), HEXO (HEXO Corp.), RVLP (RVL Pharmaceuticals plc), NVCN (Neovasc Inc.). Compare IMV side-by-side with any of them on Quantisnow.How can I track IMV on Quantisnow?
Quantisnow aggregates IMV Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMV to receive live email and push alerts on every new disclosure.